erdafitinib: Clinical Trials

15 trials of erdafitinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 3 active not recruiting, 1 terminated. 15 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 115Completed 11, Active not recruiting 3, Terminated 1
Phase 24Active not recruiting 2, Completed 2

Follow erdafitinib: new trials by email Literature Review of erdafitinib trials Research Report on erdafitinib

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
Phase 1CompletedJanssen Pharmaceutical K.K.52023-03-032026-11-03
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 1Active not recruitingNational Cancer Institute (NCI)242022-07-072026-11-20
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Erdafitinib Intravesical Delivery System - Non-Muscle Invasive Bladder Neoplasms
Phase 1 / Phase 2Active not recruitingJanssen Research & Development, LLC2352022-04-112026-11-03
A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants
Erdafitinib, Carbamazepine - Healthy
Phase 1CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.152020-03-312023-06-29
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide - Relapsed Refractory Multiple Myeloma
Phase 1 / Phase 2CompletedMultiple Myeloma Research Consortium1032019-04-012025-02-14
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Erdafitinib - Hepatic Impairment
Phase 1TerminatedJanssen Research & Development, LLC262018-12-062025-02-03
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
JNJ-63723283, Erdafitinib - Neoplasm
Phase 1CompletedJanssen Pharmaceutical K.K.222018-08-312025-04-28
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Erdafitinib, Cetrelimab, Cisplatin - Urothelial Carcinoma
Phase 1 / Phase 2Active not recruitingJanssen Research & Development, LLC1252018-04-052026-08-28
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Erdafitinib, Palbociclib, Fulvestrant - Metastatic Breast Cancer
Phase 1CompletedVanderbilt-Ingram Cancer Center352017-08-182024-11-14
A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants
Erdafitinib, Fluconazole, Itraconazole - Healthy
Phase 1CompletedJanssen Research & Development, LLC542017-04-142025-02-03
A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants
Erdafitinib - Healthy
Phase 1CompletedJanssen Research & Development, LLC162017-03-142017-06-23
A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants
JNJ-42756493 - Healthy
Phase 1CompletedJanssen Research & Development, LLC82016-03-012017-10-23
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
JNJ-42756493 (erdafitinib) - Carcinoma, Hepatocellular
Phase 1 / Phase 2CompletedJanssen Research & Development, LLC532015-05-252025-02-03
Pharmacokinetic Study of JNJ-42756493 in Healthy Participants
JNJ-42756493 10 mg tablet, JNJ-42756493 10 mg Oral Solution, JNJ-61818549 - Healthy
Phase 1CompletedJanssen Research & Development, LLC82014-10-012015-01-08
Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants
JNJ-42756493 Tablet, JNJ-42756493 Capsule, JNJ-61818549 - Healthy
Phase 1CompletedJanssen Research & Development, LLC122014-09-012014-12-03

Conditions studied

Carcinoma, Transitional Cell (2)  ·  Urinary Bladder Neoplasms (2)  ·  Acrocephalosyndactylia (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Ureteral Neoplasms (1)  ·  Urethral Neoplasms (1)

Sponsors

Janssen Research & Development, LLC (9)  ·  Janssen Pharmaceutical K.K. (2)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)  ·  Multiple Myeloma Research Consortium (1)  ·  National Cancer Institute (NCI) (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (7)  ·  Belgium (5)  ·  Japan (3)  ·  South Korea (3)  ·  Canada (2)  ·  Germany (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Belarus (1)  ·  Brazil (1)  ·  China (1)  ·  France (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)

Top investigators

Brent Rexer, MD, PhD (1)  ·  Hearn J Cho, M.D., Ph.D. (1)  ·  Rohit Jain (1)

Results publications

PMID 31673875, PMID 39971605, PMID 40627530, PMID 41538748

NIH funding

2014 (2), 2017 (2), 2023 (2), 2018 (1), 2019 (1), UM1CA186644 (1)